Artiva Biotherapeutics permanently discontinues AlloNK, its lead NK cell therapy, after a patient dies of fludarabine-linked ...

Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition — — Eligible for development incentives including 7 ...

The FDA granted Orphan Drug Designation to sovleplenib for treating primary immune thrombocytopenia, highlighting its ...

Hyderabad-based Helex Inc is working on a first-in-class mechanism to deliver gene editing drugs safely into the kidneys—a ...